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Abstract
Background: Delirium is a highly prevalent disorder among older patients in intensive care units (ICUs). Although 
antipsychotic drugs are the medications most frequently used to treat this syndrome, these drugs are associated with a 
variety of adverse events, including sedation, extrapyramidal side effects, and cardiac arrhythmias. Drug treatment for 
delirium requires careful consideration of the balance between the effective management of symptoms and potential 
adverse effects.
Methods: We report on five Japanese men (an 84 year old (acute aortic dissociation: Stanford type A), a 55 year old 
(traumatic subarachnoid hemorrhage and brain contusion), a 76 year old (sepsis by pyelonephritis), an 85 year old 
(cerebral infarction), and an 86 year old (pulmonary emphysema and severe pneumonia)) in which the selective 
serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the delirium of 
the patients.
Results: Delirium Rating Scale (DRS) scores in these five patients dramatically decreased after treatment with 
fluvoxamine.
Conclusion: Doctors should consider fluvoxamine as an alternative approach to treating delirium in ICU patients in 
order to avoid the risk of side effects and increased mortality from antipsychotic drugs.
Background
Delirium is a common complication in intensive care
units (ICUs) [1-3]. Acute syndrome caused by a distur-
bance of the cognitive processes in the brain is associated
with poor short-term outcomes and may result in adverse
sequelae years after ICU discharge [1-3]. Although the
pathophysiology of delirium is not fully understood,
accumulating evidence suggests that acute oxidative
stress responses and inflammation can all contribute to a
disruption of neurotransmission (for example, acetylcho-
line, glutamate, γ -aminobutyric acid, dopamine, sero-
tonin, norepinephrine) and, ultimately, to the
development of delirium [1-4]. Antipsychotic drugs are
the medications most frequently used to treat this syn-
drome. However, patients with treated with antipsychotic
drugs should be monitored for a variety of adverse events,
including hypotension, dystonia, extrapyramidal effects,
laryngeal spasm, malignant hyperthermia, glucose and
lipid dysregulation, and anticholinergic effects such as
dry mouth, constipation, and urinary retention [1-4].
Additionally, there is an association between antipsy-
chotic use (typical or atypical) and increased mortality in
older patients [5,6], suggesting that the widespread use of
typical and atypical antipsychotic drugs in older adults
should be re-evaluated.
The endoplasmic reticulum protein sigma-1 receptors
play key roles in Ca2+ signaling and cell survival, and have
been shown to regulate a number of neurotransmitter
systems in the brain [7-11]. The selective serotonin
reuptake inhibitor (SSRI) fluvoxamine is a very potent
agonist at sigma-1 receptors, which are also implicated in
cognition and the pathophysiology of neuropsychiatric
diseases [10,11]. A study using the selective sigma-1
receptor agonist [11C]-SA4503 and positron emission
tomography demonstrated that fluvoxamine binds to
sigma-1 receptors in the living human brain at therapeu-
tic doses, suggesting that sigma-1 receptors might be
involved in the mechanism underlying fluvoxamine's
action [12].* Correspondence: tsufuruse49@yahoo.co.jp
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regulation of neurotransmitter systems, we have a
hypothesis that fluvoxamine might be effective in the
treatment of delirium. Very recently, we reported two
cases showing that fluvoxamine was effective in amelio-
rating the delirium of patients with Alzheimer's disease
[13]. Here, we report five cases in which fluvoxamine was
also effective in the treatment of delirium in ICU
patients.
Case reports
Table 1 shows the characteristics of five ICU patients
with delirium.
Case 1
An 84-year-old Japanese man was admitted to a hospital's
emergency medical center with a complaint of stomach
ache. The patient was diagnosed with acute aortic disso-
ciation (Stanford type A) and treated in the ICU. An anal-
gesic effect of pentazocine was observed. However, he
had sleep disturbance in the night, and the patient's topic
of conversation was inappropriate. Therefore, he was
referred to the hospital's department of psychiatry. There,
he was disoriented and agitated. To treat his delirium, he
was administered fluvoxamine (50 mg, twice a day) and
flunitrazepam (1 mg, at night). At 1 day after treatment,
his sleep disturbance improved, and his Delirium Rating
Scale (DRS) [14] score decreased dramatically from 16/32
to 6/32. After ICU discharge, his condition was good. His
Mini-Mental State Examination (MMSE) [15] score was
25/30.
Case 2
A 55-year-old Japanese man fell from a ladder while
working, and a resulting bruise on his head impaired his
consciousness. He was admitted to the hospital's emer-
gency medical center. The patient was diagnosed with
traumatic subarachnoid hemorrhage and brain contusion
by brain computed tomography (CT) and magnetic reso-
nance imaging (MRI). His level of consciousness on the
Glasgow Coma Scale [16] in the emergency room was 13/
15. His grasp of consciousness was shaky, and he shouted
suddenly, whereupon he was referred to the department
of psychiatry. He was disoriented, and uttered inappro-
priate comments. To treat his delirium, fluvoxamine (50
mg, twice a day) and flunitrazepam (1 mg, at night) were
added. At 1 day after treatment, his sleep disturbance
improved, and his DRS score dramatically decreased
from 20/32 to 10/32. After rehabilitation, he recovered
gradually. His MMSE score just before discharge was 25/
30.
Case 3
A 76-year-old Japanese man was admitted to a hospital's
emergency medical center with a fever of 40°C and in a
twilight state. His body CT showed a right kidney stone,
and he was diagnosed with sepsis from pyelonephritis. At
night time, he became excited and removed his intrave-
Table 1: Demographic, clinical, and symptom characteristics of patients with delirium who responded to fluvoxamine






1 M 84 Acute aortic 
association
50 mg 16/32 6/32 (1 day)





50 mg 20/32 10/32 (1 day)
3 M 76 Sepsis by 
pyelonephritis
50-150 mg 21/32 10/32 (3 days)
4 M 85 Cerebral 
infarction
50 mg 19/32 10/32 (1 day)




50-100 mg 18/32 6/32 (2 days)
DRS = Delirium Rating Scale.
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department of psychiatry. He was disoriented and could
not remember why he was in the hospital. A brain CT
showed brain atrophy and ventricular enlargement. He
had delirium associated with cognitive impairment. To
treat the delirium, fluvoxamine (50 mg, twice a day) and
flunitrazepam (1 mg, at night) were added. His sleep dis-
turbance improved, but he became agitated. His fluvox-
amine dosage was therefore increased to 100 mg and
then, the next day, to 150 mg. At 3 days after the start of
treatment, his DRS score decreased dramatically from
21/32 to 10/32. His MMSE score just before discharge
was 22/30.
Case 4
An 85-year-old Japanese man was admitted to the emer-
gency medical center with a complaint of languidness on
the left side of his body after he fell in the bathroom at his
home. The patient was diagnosed with cerebral infarction
by brain CT and MRI. At 2 days after hospitalization, he
had sleep disturbance and excitation. He was therefore
referred to the department of psychiatry. He was also dis-
oriented and agitated. To treat his delirium, fluvoxamine
(50 mg, twice a day) and flunitrazepam (1 mg, night) were
added. His sleep disturbance improved. At 1 day after this
treatment, his DRS score decreased dramatically from
19/32 to 10/32. His MMSE score just before discharge
was 22/30.
Case 5
An 86-year-old Japanese man was admitted to our emer-
gency medical center because he had entered a twilight
state after falling in the bathroom at his home. His percu-
taneous arterial oxygen saturation (SpO2) level was 80%,
though oxygen was administered with a mask. The
patient was diagnosed with pulmonary emphysema and
severe pneumonia by chest x-ray and chest CT. To treat
the patient's severe pneumonia, antibiotics and steroids
were administered. On the night of his fourth day of hos-
pitalization, he became excited suddenly and said that he
wanted to go home if other people had contempt for him.
He became more excited and booed at a nurse. The next
day, he was referred to the department of psychiatry.
Although he was not disoriented, he had some delusions;
he claimed that a nurse was poisoning his intravenous
drip and that a stranger was spying on him. To treat his
delirium, fluvoxamine (50 mg, twice a day) and fluni-
trazepam (1 mg, at night) were added. The next day, his
fluvoxamine dosage was increased to 100 mg. At 2 days
after the first administration, his DRS score decreased
rapidly, from 18/32 to 6/32. At 1 week after the initiation
of treatment, his fluvoxamine dosage was reduced to 50
mg. His MMSE score just before discharge (after 4 weeks
of hospitalization) was 25/30.
Discussion
To our knowledge, this report is the first to demonstrate
that fluvoxamine is rapidly effective for treating delirium
in ICU patients. Nonetheless, a randomized double-
blind, placebo-controlled study of fluvoxamine will be
needed to confirm its efficacy for the treatment of delir-
ium in ICU patients. Recent findings suggest that sigma-1
receptors might be involved in the different mechanisms
of some SSRIs, and that fluvoxamine is a potent sigma-1
receptor agonist [9-11]. Currently, it is unclear whether
sigma-1 receptors were involved in the mechanism
underlying the beneficial effects of fluvoxamine against
the delirium of these ICU patients. Interestingly, donepe-
zil, a potent sigma-1 receptor agonist [17-19], was
reported to be effective for treating delirium [20-22],
although further studies are necessary. In order to con-
firm the role of sigma-1 receptors in the treatment of
delirium, a randomized double-blind, placebo-controlled
study of the selective sigma-1 receptor agonists (for
example, cutamesine (SA4503)) in ICU patients with
delirium would also be of interest.
Delirium is theorized to be a neurobehavioral manifes-
tation of imbalances in the synthesis, release, and inacti-
vation of a number of neurotransmitters that normally
control cognitive function, behavior, and mood [1-4]. At
present, it is unclear whether fluvoxamine monotherapy
is effective for certain domains of delirium symptoms or
for all delirium symptoms equally. Given the role of
sigma-1 receptors in the regulation of a number of neu-
rotransmitters, as well as in cognition and mood [7-11], it
is likely that sigma-1 receptor agonist may be involved in
the fluvoxamine's mechanisms of action, although further
study will be necessary.
In this study, in all patients a low dose of flunitrazepam
was used for the treatment of insomnia since this drug is
considered to be one of the most effective benzodiaz-
epine hypnotics. Therefore, we cannot exclude a possible
contribution of flunitrazepam to the efficacy of fluvox-
amine for delirium. A further study of fluvoxamine alone
will be necessary. In addition, from the present study, we
cannot exclude a potential contribution of serotonin
transporter inhibition by fluvoxamine to ameliorate delir-
ium in ICU patients. However, it has been reported that
the combination of SSRIs with antipsychotic drug(s) and
concomitant benztropine might increase the risk of delir-
ium in patients. Byerly et al. [23] reported a case showing
delirium associated with sertraline, haloperidol and ben-
zotropine. Furthermore, Armstrong et al. [24] reported a
case of delirium in a patient who was taking benztropine
and paroxetine concomitantly. At present, the precise
mechanisms underlying the incidence of delirium associ-
ated with the combination of sertraline (or paroxetine)
and benztropine are currently unclear. Recent findings
suggest that sigma-1 receptors might be involved in dif-
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potent sigma-1 receptor agonist, and sertraline may be a
sigma-1 receptor antagonist [10]. Paroxetine has a very
low affinity at sigma-1 receptors [10]. Taken together, it is
likely that agonism of fluvoxamine at sigma-1 receptors
may be involved in the mechanisms of beneficial effects
of this SSRI although a further detailed study is necessary.
Drug treatment for delirium requires careful consider-
ation of the balance between the effective management of
symptoms and potential adverse effects. As mentioned
above, there is an elevated risk of mortality in older
patients treated with atypical antipsychotics [5,6], sug-
gesting that the widespread use of atypical antipsychotic
drugs in older adults should be re-evaluated. Therefore,
the sigma-1 receptor agonist fluvoxamine may serve as an
alternative treatment option for older adults with delir-
ium, although further detailed studies on the role of
sigma-1 receptors in delirium are necessary.
Conclusions
These five cases suggest that the sigma-1 receptor agonist
fluvoxamine could be an alternative approach to treating
delirium in ICU patients because of the risk of extrapyra-
midal side effects and increased mortality from antipsy-
chotic drugs. More detailed double-blind studies should
be performed to clarify the role of sigma-1 receptors in
the efficacy of fluvoxamine for delirium in ICU patients.
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